OBJECTIVES: To utilize cytokine levels to predict sustained response (SR) to alpha interferon (IFN alpha) therapy in chronic hepatitis C patients, and to determine the relationship between serum tumor necrosis factor alpha (TNF alpha), interleukin (IL) IL 6, IL 8, IL 12, transforming growth factor beta (TGF beta 1) and the degree of liver damage as reflected by traditional markers. DESIGN AND METHODS: Serum cytokine levels were assessed using ELISA in 18 patients included in a controlled clinical trial of IFN alpha. RESULTS: Of the 18 patients, 27% were sustained responders (SR), 27% were response and relapse responders (RR), and 46% were non-responders (NR). Multivariate analysis showed that a low serum TNF alpha level and high serum IL 8 levels were independent factors associated with SR to IFN alpha therapy. Serum TNF alpha level highly correlated with viral load and genotype predictive values (p < 0.001). Therapy lowered the IL 6 and IL 12 profile. TGF beta 1 levels in serum are positively correlated with fibrinogenesis. CONCLUSIONS: IFN alpha therapy modulates immune response to hepatitis C virus, contributing to sustained response.
OBJECTIVES: To utilize cytokine levels to predict sustained response (SR) to alpha interferon (IFN alpha) therapy in chronic hepatitis Cpatients, and to determine the relationship between serum tumor necrosis factor alpha (TNF alpha), interleukin (IL) IL 6, IL 8, IL 12, transforming growth factor beta (TGF beta 1) and the degree of liver damage as reflected by traditional markers. DESIGN AND METHODS: Serum cytokine levels were assessed using ELISA in 18 patients included in a controlled clinical trial of IFN alpha. RESULTS: Of the 18 patients, 27% were sustained responders (SR), 27% were response and relapse responders (RR), and 46% were non-responders (NR). Multivariate analysis showed that a low serum TNF alpha level and high serum IL 8 levels were independent factors associated with SR to IFN alpha therapy. Serum TNF alpha level highly correlated with viral load and genotype predictive values (p < 0.001). Therapy lowered the IL 6 and IL 12 profile. TGF beta 1 levels in serum are positively correlated with fibrinogenesis. CONCLUSIONS:IFN alpha therapy modulates immune response to hepatitis C virus, contributing to sustained response.
Authors: Marc Weeber; Rein Vos; Henny Klein; Lolkje T W De Jong-Van Den Berg; Alan R Aronson; Grietje Molema Journal: J Am Med Inform Assoc Date: 2003-01-28 Impact factor: 4.497
Authors: Jason T Blackard; Minhee Kang; Kenneth E Sherman; Margaret James Koziel; Marion G Peters; Raymond T Chung Journal: J Interferon Cytokine Res Date: 2006-11 Impact factor: 2.607
Authors: K Ishii; N Takamura; E Shinohara; H Y Shin; T Ikehara; S Hata; T Kawafune; Y Sumino; Y Ohmoto Journal: Dig Dis Sci Date: 2002-04 Impact factor: 3.199
Authors: Curtis Cooper; Stephan Shafran; Susan Greenbloom; Robert Enns; John Farley; Nir Hilzenrat; Kurt Williams; Magdy Elkashab; Nabil Abadir; Manuela Neuman Journal: Can J Gastroenterol Hepatol Date: 2013-11-08
Authors: Jason T Blackard; Minhee Kang; J Benjamin St Clair; Wenyu Lin; Yoshitaka Kamegaya; Kenneth E Sherman; Margaret James Koziel; Marion G Peters; Janet Andersen; Raymond T Chung Journal: J Interferon Cytokine Res Date: 2007-04 Impact factor: 2.607
Authors: Jacqueline Estevez; Vincent L Chen; Ondrej Podlaha; Biao Li; An Le; Philip Vutien; Ellen T Chang; Yael Rosenberg-Hasson; Zhaoshi Jiang; Stefan Pflanz; Dongliang Ge; Anuj Gaggar; Mindie H Nguyen Journal: Sci Rep Date: 2017-09-19 Impact factor: 4.379